BNP Paribas Financial Markets Purchases 12,432 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

BNP Paribas Financial Markets grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 80.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,829 shares of the medical instruments supplier's stock after buying an additional 12,432 shares during the quarter. BNP Paribas Financial Markets owned 0.12% of LeMaitre Vascular worth $2,585,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Summit Global Investments increased its holdings in shares of LeMaitre Vascular by 2.4% during the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock valued at $575,000 after purchasing an additional 146 shares during the period. Shaker Investments LLC OH boosted its holdings in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier's stock worth $1,138,000 after buying an additional 175 shares in the last quarter. NBC Securities Inc. boosted its stake in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 183 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock valued at $68,000 after purchasing an additional 188 shares during the last quarter. Finally, nVerses Capital LLC boosted its position in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after purchasing an additional 200 shares during the period. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

LMAT traded down $1.36 during trading on Friday, reaching $101.12. The company had a trading volume of 117,237 shares, compared to its average volume of 107,449. LeMaitre Vascular, Inc. has a 12 month low of $52.72 and a 12 month high of $109.58. The business's fifty day moving average price is $96.82 and its 200 day moving average price is $88.78. The company has a market cap of $2.27 billion, a P/E ratio of 55.26, a PEG ratio of 2.57 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular's quarterly revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business earned $0.33 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

Wall Street Analyst Weigh In

LMAT has been the subject of several research analyst reports. StockNews.com raised LeMaitre Vascular from a "hold" rating to a "buy" rating in a research note on Thursday. JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. Oppenheimer restated an "outperform" rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research upped their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $94.57.

Insider Activity

In other news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company's stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.